rs8087522 — MC4R MC4R A/G (rs8087522)

Upstream regulatory variant near MC4R that may create a transcription factor binding site, with emerging evidence linking the A allele to greater weight gain during clozapine treatment

See your personal result for MC4R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MC4R Upstream Variant — A Regulatory Tag in the Appetite Control Region

The melanocortin-4 receptor (MC4R) is the central satiety switch in the brain's hypothalamic energy balance circuit11 hypothalamic energy balance circuit
the hypothalamus integrates signals from fat cells, gut hormones, and the brainstem to regulate hunger and energy expenditure. When the MC4R pathway is working, leptin from fat cells activates POMC neurons that release alpha-melanocyte stimulating hormone (α-MSH), which binds MC4R receptors and sends "stop eating" signals. The rs8087522 variant sits approximately 2 kilobases upstream of the MC4R gene — in the regulatory DNA that controls how much MC4R the hypothalamus produces.

This is a depth variant. The GeneOps platform already covers rs1778231322 rs17782313
the primary MC4R-region obesity GWAS signal, 188kb downstream of MC4R, which has a robust obesity association replicated in tens of thousands of participants. rs8087522 sits directly upstream of MC4R's coding sequence and tags a different aspect of MC4R regulation. Its specific clinical relevance has emerged primarily in the context of medication-induced weight gain rather than general obesity.

The Mechanism

rs8087522 is a G-to-A substitution at position 60,373,245 on chromosome 18 (GRCh38), approximately 2kb upstream of the MC4R transcription start site. MC4R itself is encoded on the minus strand, but rs8087522 alleles are reported in plus-strand orientation (G=reference, A=alternate).

In vitro electrophoretic mobility-shift assay33 In vitro electrophoretic mobility-shift assay
EMSA: a technique where protein extracts are incubated with labeled DNA to detect transcription factor binding data from one pharmacogenomics study suggest that the A allele may create a transcription factor binding site absent in the G allele. If confirmed, this would give the A allele the capacity to alter MC4R upstream regulatory activity — potentially changing how much receptor protein is expressed in hypothalamic neurons. However, this functional evidence is limited to a single in vitro assay and has not been replicated in human brain tissue or animal models.

The nearby rs48969344 rs489693
a variant ~158kb upstream of rs8087522 on chromosome 18, mapped near the MC4R region in GWAS studies has been independently associated with antipsychotic-induced weight gain at genome-wide significance (P=5.59×10⁻¹²), confirming that the MC4R upstream regulatory region as a whole influences medication-related energy dysregulation.

The Evidence

Direct evidence for rs8087522 is sparse and should be read honestly:

General obesity: Two studies have directly tested rs8087522 for obesity association and found none. Beckers et al. (2011)55 Beckers et al. (2011)
association study of MC4R tagSNPs in 1,049 obese Belgian adults vs. 312 lean controls genotyped rs8087522 alongside rs17782313 and rs1943226 and found "no associations with obesity" for the upstream variants, while rs17782313 replicated strongly (OR=1.42, p=0.002). Yilmaz et al. (2015)66 Yilmaz et al. (2015)
328 European ancestry individuals, five MC4R markers similarly found no independent rs8087522 signal for BMI or overeating behaviors.

Antipsychotic-induced weight gain: The most specific finding for rs8087522 comes from Chowdhury et al. (2012)77 Chowdhury et al. (2012)
224 schizophrenia patients on antipsychotics, 14-week follow-up. European-ancestry patients carrying the A allele who were taking clozapine gained significantly more weight than non-carriers (P=0.027, n=69 in the clozapine subgroup). The authors caution that this association was marginal after correction for multiple testing and described the findings as exploratory, warranting further investigation. The proposed mechanism — A-allele creation of a transcription factor binding site (confirmed by EMSA) — adds biological plausibility, but the clinical signal remains unconfirmed.

The broader context for MC4R upstream variants in antipsychotic weight gain is stronger. The nearby rs489693 reached genome-wide significance in a multi-cohort study of 344 pediatric and adult patients (meta-analysis P=5.59×10⁻¹²), with minor allele homozygotes gaining substantially more weight on second-generation antipsychotics including clozapine, olanzapine, and quetiapine. The rs489693 finding has been independently replicated, making the MC4R upstream region a credible antipsychotic pharmacogenomics locus even if the specific contribution of rs8087522 within that region remains to be established.

Practical Implications

For individuals prescribed clozapine specifically, A-allele status at rs8087522 may be one element of a broader MC4R-region pharmacogenomic risk profile. Clozapine is disproportionately associated with weight gain among antipsychotics — average gain of 4-6 kg over the first year — and MC4R pathways are mechanistically implicated in how the drug suppresses hypothalamic satiety neurons. The A allele's potential to alter MC4R upstream regulation means that individuals carrying it on clozapine may warrant closer metabolic monitoring from the start of treatment.

For general weight management outside of antipsychotic use, the current evidence does not support rs8087522 as an independent risk factor. The primary MC4R-region signal for common obesity risk remains rs17782313, which has a well-established, large-cohort evidence base.

Interactions

rs17782313 (the primary MC4R-region obesity variant): rs17782313 is located 188kb downstream of MC4R in a separate regulatory block and has a robust, independent obesity association. rs8087522 sits in the proximal upstream region and has been tested in studies alongside rs17782313 — in those studies, the two variants do not show correlated effects on obesity. They likely tag different aspects of MC4R regulation and should be interpreted independently.

rs489693 (MC4R-region antipsychotic pharmacogenomics variant): rs489693 lies roughly 157kb from rs8087522 on chromosome 18 and has a strong, replicated association with antipsychotic-induced weight gain (genome-wide significance in multi-cohort GWAS). Both variants tag the MC4R regulatory region in the context of drug-induced weight gain, and their combined effect has not been formally studied. Individuals carrying risk alleles at both loci may face amplified antipsychotic weight gain risk, though this is speculative without published compound-genotype data.

Drug Interactions

clozapine increased_toxicity literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Common Regulatory Variant Normal

Common GG genotype — standard MC4R upstream regulatory sequence

You carry two copies of the G allele, the reference sequence at the rs8087522 locus upstream of MC4R. About 48% of people of European descent share this genotype. Current evidence does not associate the GG genotype with altered obesity risk or antipsychotic- induced weight gain. Your MC4R upstream regulatory region is in its common configuration.

AG A-Allele Carrier Intermediate

One A allele — possible upstream MC4R regulatory effect

The pharmacogenomic signal at rs8087522 emerged specifically in the context of clozapine treatment. In Chowdhury et al. (2012), 69 European-ancestry schizophrenia patients on clozapine were analyzed; A-allele carriers gained significantly more weight (P=0.027) than non-carriers. The finding was exploratory and not corrected for multiple comparisons, so it should be interpreted cautiously. If you are prescribed clozapine or are being considered for it, this result is worth flagging to your prescribing physician as part of a broader metabolic monitoring conversation — not as a reason to avoid the medication.

The broader MC4R upstream region context strengthens the plausibility of this signal. The nearby rs489693 (a different MC4R-region SNP) has a genome-wide significant association with antipsychotic-induced weight gain (P=5.59×10⁻¹²) in pediatric and adult patients, confirming that MC4R upstream variants collectively influence how antipsychotic drugs affect hypothalamic appetite circuits.

AA Homozygous A Allele High Risk

Two A alleles — highest MC4R upstream risk configuration for antipsychotic weight gain

rs8087522 sits 2kb upstream of MC4R in a region where the A allele may alter transcription factor binding (in vitro EMSA evidence). The functional consequence — if the A allele upregulates or dysregulates MC4R expression — would be relevant to any scenario where hypothalamic MC4R tone is challenged: antipsychotic treatment, extreme caloric restriction, or states of high cortisol.

The broader pharmacogenomics picture for the MC4R upstream region is well-established. rs489693, a nearby MC4R-region variant, was identified in a GWAS of antipsychotic- induced weight gain reaching genome-wide significance (P=5.59×10⁻¹²). Patients who were minor-allele homozygotes at rs489693 gained 2.2× more weight on second-generation antipsychotics over 12 weeks, with effects extending to triglycerides, leptin, and insulin. While rs8087522 and rs489693 are distinct variants, they both implicate the MC4R upstream regulatory region in antipsychotic pharmacogenomics.

In the absence of antipsychotic exposure, rs8087522 AA has not been shown to independently increase obesity risk in published general-population studies. Your primary MC4R-region obesity signal is carried by other variants with larger, replicated effect sizes in general population studies.